231 related articles for article (PubMed ID: 31070022)
1. Optimizing checkpoint inhibitors therapy for relapsed or progressive classic Hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment.
Carbone A; Gloghini A; Pruneri G; Dolcetti R
Cancer Med; 2019 Jun; 8(6):3012-3016. PubMed ID: 31070022
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint inhibition therapy as possible frontline therapy for Hodgkin lymphoma.
Khurana A; Armand P; Ansell SM
Leuk Lymphoma; 2020 May; 61(5):1063-1074. PubMed ID: 31914840
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy in Relapsed or Refractory Classic Hodgkin's Lymphoma Treated with PD-1 Inhibitors: A Meta-Analysis of 9 Prospective Clinical Trials.
Zhang X; Chen L; Zhao Y; Yin H; Ma H; He M
Biomed Res Int; 2019; 2019():9283860. PubMed ID: 31950058
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
Villasboas JC; Ansell S
Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of Hodgkin Lymphoma: Mobilizing the Patient's Immune Response.
Ansell SM
Cancer J; 2018; 24(5):249-253. PubMed ID: 30247261
[TBL] [Abstract][Full Text] [Related]
6. Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment.
Mikkilineni L; Whitaker-Menezes D; Domingo-Vidal M; Sprandio J; Avena P; Cotzia P; Dulau-Florea A; Gong J; Uppal G; Zhan T; Leiby B; Lin Z; Pro B; Sotgia F; Lisanti MP; Martinez-Outschoorn U
Semin Oncol; 2017 Jun; 44(3):218-225. PubMed ID: 29248133
[TBL] [Abstract][Full Text] [Related]
7. [Checkpoint inhibitors in Hodgkin lymphoma].
Sasse S; Momotow J; Engert A
Internist (Berl); 2020 Jul; 61(7):660-668. PubMed ID: 32462248
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibition in classical hodgkin lymphoma.
Pezeshki PS; Eskian M; Hamblin MR; Rezaei N
Expert Rev Anticancer Ther; 2021 Sep; 21(9):1003-1016. PubMed ID: 33857395
[No Abstract] [Full Text] [Related]
9. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
10. Digital spatial profiling of CD4
Takeuchi M; Miyoshi H; Semba Y; Yamada K; Nakashima K; Sato K; Furuta T; Moritsubo M; Ogura Y; Tanaka K; Imamoto T; Arakawa F; Kohno K; Ohshima K
Virchows Arch; 2023 Aug; 483(2):255-260. PubMed ID: 37270432
[TBL] [Abstract][Full Text] [Related]
11. Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors.
Vardhana S; Cicero K; Velez MJ; Moskowitz CH
Oncologist; 2019 Jan; 24(1):86-95. PubMed ID: 30082490
[TBL] [Abstract][Full Text] [Related]
12. Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma.
Carbone A; Gloghini A; Carlo-Stella C
Blood; 2023 May; 141(18):2187-2193. PubMed ID: 36898085
[TBL] [Abstract][Full Text] [Related]
13. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.
Kasamon YL; de Claro RA; Wang Y; Shen YL; Farrell AT; Pazdur R
Oncologist; 2017 May; 22(5):585-591. PubMed ID: 28438889
[TBL] [Abstract][Full Text] [Related]
14. Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma.
Calabretta E; d'Amore F; Carlo-Stella C
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31694167
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
16. Targeting Immune System Alterations in Hodgkin Lymphoma.
Grover NS; Savoldo B
Curr Hematol Malig Rep; 2017 Aug; 12(4):358-369. PubMed ID: 28780614
[TBL] [Abstract][Full Text] [Related]
17. Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance.
Aldinucci D; Celegato M; Casagrande N
Cancer Lett; 2016 Sep; 380(1):243-52. PubMed ID: 26474544
[TBL] [Abstract][Full Text] [Related]
18. Future directions in Hodgkin lymphoma: checkpoint inhibitors and beyond.
Desai S; Ansell SM
Leuk Lymphoma; 2021 Aug; 62(8):1795-1804. PubMed ID: 33602008
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint Inhibition in Hodgkin Lymphoma - a Review.
Bröckelmann PJ; Engert A
Oncol Res Treat; 2017; 40(11):654-660. PubMed ID: 29065424
[TBL] [Abstract][Full Text] [Related]
20. [Microenvironment in classical Hodgkin lymphoma].
Mottok A
Pathologe; 2020 May; 41(3):254-260. PubMed ID: 32239325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]